Umbilical cord blood or HLA-haploidentical transplantation: Real world outcomes vs randomized trial outcomes.

[1]  R. Soiffer,et al.  HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. , 2021, Blood.

[2]  E. Leifer,et al.  Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. , 2021, Blood.

[3]  K. Ballen,et al.  Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant. , 2020, Biology of Blood and Marrow Transplantation.

[4]  S. Montoto,et al.  Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Wagner,et al.  Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Labopin,et al.  Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide , 2018, Cancer.

[7]  P. Hari,et al.  Current Use and Trends in Hematopoietic Cell Transplantation in the United States. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  C. Furberg,et al.  The necessity for clinical reasoning in the era of evidence-based medicine. , 2013, Mayo Clinic proceedings.

[9]  J. Wagner,et al.  Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. , 2013, Blood.

[10]  Xu Zhang,et al.  A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model , 2007, Comput. Methods Programs Biomed..

[11]  Harlan M Krumholz,et al.  Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.

[12]  John O'Quigley,et al.  Proportional hazards models with frailties and random effects , 2002, Statistics in medicine.

[13]  David Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials , 2001, Annals of Internal Medicine.

[14]  J P Klein,et al.  Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. , 1999, Statistics in medicine.

[15]  D.,et al.  Regression Models and Life-Tables , 2022 .